Results From a Randomized, Open-Label, Crossover Study Evaluating the Effect of the Aldosterone Synthase Inhibitor Baxdrostat on the Pharmacokinetics of Metformin in Healthy Human Subjects

ConclusionThe results of this study suggest that diabetic patients with hypertension receiving both metformin and baxdrostat are unlikely to require dose adjustment.RegistrationClinicalTrials.gov identifier no. NCT05526690.Graphical Abstract
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research